On 25 July 2012, the European Commission announced that it had sent a formal Statement of Objections (“SO”) to Danish pharmaceutical company Lundbeck over its conclusion of so-called “pay-for-delay” agreements with four generic producers of citalopram, a antidepressant medicine. In its SO, the Commission alleges that Lundbeck concluded agreements with generic producers of citalopram to prevent the entry of generic versions of the medicine on the market, contrary to Article 101 TFEU. In theory, entry on the market of generic versions of citalopram should have been possible when some of
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.